Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

480 mg intravenous Nivolumab administered every 4 weeks.

"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."